HOUSTON--(BUSINESS WIRE)--Pharm-Olam International LLC, a multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the appointment of John Barry as Chief Operating Officer.
As the Chief Operating Officer, Mr. Barry will be responsible for the oversight of Pharm-Olam’s Clinical Operations, Project Management, Medical Affairs, Data Management, Biostatistics, and Client Relations teams. Mr. Barry has extensive experience in the drug development industry and has worked as executive leader for two of the top 5 CROs and was previously with Merck as the Head of Portfolio Sourcing and Relationship Management.
“John is a proven industry veteran and represents a cornerstone for future Pharm-Olam growth,” said David L. Grange, CEO at Pharm-Olam International. “John’s experience at some of the largest CROs combined with the skill of sourcing vendors for a pharmaceutical company is a unique skill set that will provide exclusive insight and guidance for Pharm-Olam as we continue to grow into the premier mid-size CRO in the industry.”
Pharm-Olam operates in more than 60 countries worldwide, offering end-to-end clinical trial support for Phase I-IV clinical trials. More information about Pharm-Olam and its full-service capabilities and offerings are available at www.Pharm-Olam.com, or by request via email firstname.lastname@example.org.
About Pharm-Olam International Group
Pharm-Olam International is a multinational Contract Research Organization (CRO) offering comprehensive clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines, making clinical research as Easy As I, II, III, IV™. For further information about Pharm-Olam, please visit www.pharm-olam.com.